Page 898«..1020..897898899900..910920..»

Curi Bio Announces Mantarray Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics – Business Wire

Posted: September 16, 2020 at 1:59 pm

SEATTLE--(BUSINESS WIRE)--Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the Mantarray platform for human-relevant 3D engineered muscle tissue (EMT) analysis. Curis Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles. By providing drug developers human-relevant tissue-specific biosystems in the preclinical stage of drug development, Curi aims to help pharmaceutical partners develop safer and more effective therapeutics in less time, at lower cost. Curi Bio is currently partnering with several leading pharmaceutical companies to accelerate the development of the Mantarray platform and to apply it to drug discovery and development projects.

Cardiovascular diseases often involve a gradual loss of cardiac contractile strength and function, ultimately leading to heart failure. Cardiomyocytes derived from human induced pluripotent stem cells (iPSC-CMs) offer a promising route to model the contractile deficiencies seen in the hearts of patients with cardiovascular diseases. However, 2D cell models lack the physiologically relevant structure and function of 3D models. As a result, 3D engineered muscle tissues have been growing in use in the drug development industry. Yet existing 3D EMT solutions are complex and low throughput, often relying on laborious serial optical imaging of each tissue to measure contractility.

Curi will make the Mantarray platform available to pharmaceutical and research customers as a standalone bioscience instrument together with multiwell consumable plates for casting and assaying EMTs. Curi will also offer service contracts and partnerships leveraging the Mantarray technology for applications in drug discovery, disease modeling, and safety and efficacy screening. Curis Mantarray platform leverages a proprietary, label-free, non-optical, electromagnetic measurement system for direct contractility assessment of up to 24 parallel iPSC-derived 3D engineered muscle tissues simultaneously. With the Mantarray platform, scientists can achieve clinically relevant functional measurements of human iPSC-derived engineered muscle tissue contractility, with a throughput and reproducibility compatible with higher-throughput screening workflows. Mantarray brings clinically relevant functional data into the earliest stages of preclinical testing of new medicines.

Leveraging human iPSC-derived cells, Mantarray 3D tissues can be used to create high-fidelity models of human diseases. For example, Mantarray 3D EMTs can be gene-edited with a CRISPR/Cas9 system to model human diseases such as Duchenne muscular dystrophy and various cardiomyopathies. Multi-modal Mantarray data show enhanced disease stratification providing researchers with more physiological data for the discovery and validation of new therapeutics.

The Mantarray platform also provides a breakthrough cardiotoxicity safety and efficacy testing platform with novel magnetic detection of drug-induced contractile changes. The magnetic detection approach can measure both acute and chronic drug responses. Drugs can be measured on the order of seconds to minutes with enough sensitivity to measure dose-response-like behavior. Alternatively, longer-term chronic experiments can be performed over the course of days. Applications include acute and chronic structural cardiotoxicity evaluation.

At Curi Bio, our goal is to provide researchers with innovative human-relevant cells, systems, and data to accelerate the discovery of new medicines, said Curi CEO Michael Cho. By providing drug developers unprecedented access to clinically-relevant preclinical models that more closely recapitulate human cardiac and skeletal muscle tissue, Curi is closing the gap between preclinical results and clinical impact.

Dr. Nicholas Geisse, Chief Science Officer of Curi Bio, will present Curis Mantarray platform and Curis recently announced ComboMat platform in a presentation at the Discovery on Target 2020 Virtual Conference.

Event: Discovery on Target 2020Date: Thursday, September 17, 2020Time: 11:15 AM EDTSession: Disease ModelingTitle: Structural Maturation in the Development of hiPSC-Cardiomyocyte Models for Preclinical Safety, Efficacy, and Discovery

Curis Mantarray platform integrates proprietary methods and IP exclusively licensed to Curi Bio by the University of Washington.

To learn more about how the Mantarray platform can improve the predictive power of 3D EMTs, or about Curis other human-relevant preclinical platform technologies and services, please reach out at http://www.curibio.com/contact.

About Curi Bio

Curi Bios preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data. Curis suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissueswith a focus on cardiac, musculoskeletal, and neuromuscular modelsfor the discovery, safety testing, and efficacy testing of new drugs in development. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

Read this article:
Curi Bio Announces Mantarray Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics - Business Wire

Posted in Stem Cells | Comments Off on Curi Bio Announces Mantarray Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics – Business Wire

What it’s like to be director of patient services for Anthony Nolan – Telegraph.co.uk

Posted: September 16, 2020 at 1:59 pm

For Chiara DeBiase, seeing the effects of the work carried out by blood cancer charity Anthony Nolan for whom she is director of patient services is what drives her. Its hugely important to Chiara that people are inspired to take the blood cancer charity to heart, fundraise for it and support it. For that, she holds the charitys founder Shirley Nolan in the highest regard. It always comes back to Shirley Nolan, she says. Shes the person that inspired and still inspires so many of our supporters, connecting everyone with her attitude of Ill do anything to save my childs life.

She turned her life upside down for Anthony, and although we didnt find a stem cell donor in time for him, she continued on her quest for everyone else in a similar situation. Everything I do comes back to that Shirley and Anthony Nolan and the desperation of her search, the tragedy of her bereavement and that she kept going for others. She was a force to be reckoned with.

Chiaras first post with Anthony Nolan was as head of patient experience over seven years ago, which was an entirely new role. Im a clinician and have worked in transplant services, and I was very excited at the way this post was dedicated to patients and their families, she says. Up until then everything was focused on getting the cells to the patients but what happened after the transplant didnt have the same dedicated focus, so I saw the role as essentially closing the circle when it came to the care Anthony Nolan provided, 40 years after it all began.

It always comes back to Shirley. Shes the person that inspired and still inspires so many of our supporters

Everything Chiaras team has done has been driven by the patients voice and the vision of ensuring every transplant patient has access to Anthony Nolan specialist care, which is funded by supporters. One of my proudest moments was when we managed to raise the funds to appoint the first three clinical nurse specialist [CNS] posts, she says. I knew the value that would bring to patients care. We now have a team of 12 CNSs and three clinical psychologists working in 12 of the 33 hospitals in the UK providing stem cell transplants. We hope that over the next three to four years we will have enough funding to have at least one Anthony Nolan post in each hospital.

That dedicated care and support given to patients post-transplant is what Chiara and her team constantly focus on, aiming to continually increase staff capacity and improve patient care. The hardest days are when Im made sharply aware that we need to do more, she says. Sometimes patients have a successful transplant and then die because of side effects like graft-versus-host disease [where the donated bone marrow or peripheral blood stem cells see the recipient's body as foreign, and the donated cells/bone marrow attack the body] and that is heart-breaking.

You think: really? After all this? Their bravery and determination You could cry.

The best moments are equally emotional, though obviously at the other end of the scale. I took a team to the British Transplant Games in 2015 and Ill never forget watching the parents of a four-year-old girl whod had a successful transplant and was taking part in the 60 metre dash, she says. The expression on their faces as she pounded towards them will stay with me forever as will a man weeping with happiness as he watched his little boy play tennis.

What Anthony Nolan does for families is what makes me love my job and makes me even more determined to provide the same for others.

Chiara feels a great responsibility not just to the patients but to the financial supporters of Anthony Nolan who make the work possible. In terms of recovery, we have two main aims, she says. Funding clinical trials, which are key to success, and also to provide equity of access to dedicated care. These supporters make that work possible and in turn save so many lives, so its hardly surprising that Im always saying: is this a good use of our money? Would Shirley approve? I think she would.

This article is an advertisement feature for Anthony Nolan.

Every day, Anthony Nolan matches incredible individuals willing to donate their stem cells or bone marrow to people with blood cancer and blood disorders who desperately need lifesaving transplants.

You can help save more lives.Every financial donation helps give more people with blood cancer a second chance of life. Without your support, there is no cure.

Visit anthonynolan.org/savelives and help save lives today.

Go here to see the original:
What it's like to be director of patient services for Anthony Nolan - Telegraph.co.uk

Posted in Stem Cells | Comments Off on What it’s like to be director of patient services for Anthony Nolan – Telegraph.co.uk

How the Hormones You’re Born With Influence Disease Risk – Technology Networks

Posted: September 16, 2020 at 1:59 pm

Differences in biological sex can dictate lifelong disease patterns, says a new study by Michigan State University researchers that links connections between specific hormones present before and after birth with immune response and lifelong immunological disease development.

Published in the most recent edition of the Proceedings of the National Academy of Sciences, the study answers questions about why females are at increased risk for common diseases that involve or target the immune system like asthma, allergies, migraines and irritable bowel syndrome. The findings by Adam Moeser, Emily Mackey and Cynthia Jordan also open the door for new therapies and preventatives.

This research shows that its our perinatal hormones, not our adult sex hormones, that have a greater influence on our risk of developing mast cell-associated disorders throughout the lifespan, says Moeser, Matilda R. Wilson Endowed Chair, professor in the Department of Large Animal Clinical Sciences and the studys principle investigator. A better understanding of how perinatal sex hormones shape lifelong mast cell activity could lead to sex-specific preventatives and therapies for mast cell-associated diseases."

Mast cells are white blood cells that play beneficial roles in the body. They orchestrate the first line of defense against infections and toxin exposure and play an important role in wound healing, according to the study, Perinatal Androgens Organize Sex Differences in Mast Cells and Attenuate Anaphylaxis Severity into Adulthood.

However, when mast cells become overreactive, they can initiate chronic inflammatory diseases and, in certain cases, death. Moesersprior research linked psychological stress to a specific mast cell receptor and overreactive immune responses.

Moeser also previously discovered sex differences in mast cells.Female mast cells store and release more inflammatory substanceslike proteases, histamine and serotonin, compared with males. Thus, female mast cells are more likely than male mast cells to kick-start aggressive immune responses. While this may offer females the upper hand in surviving infections, it also can put females at higher risk for inflammatory and autoimmune diseases.

IBS is an example of this, says Mackey, whose doctoral research is part of this new publication.

While approximately 25% of the U.S. population is affected by IBS,women are up to four times more likelyto develop this disease than men.

Moeser, Mackey and Jordans latest research explains why these sex-biased disease patterns are observed in both adults and prepubertal children. They found that lower levels of serum histamine and less-severe anaphylactic responses occur in males because of their naturally higher levels of perinatal androgens, which are specific sex hormones present shortly before and after birth.

Mast cells are created from stem cells in our bone marrow, Moeser said. High levels of perinatal androgens program the mast cell stem cells to house and release lower levels of inflammatory substances, resulting in a significantly reduced severity of anaphylactic responses in male newborns and adults.

We then confirmed that the androgens played a role by studying males who lack functional androgen receptors, says Jordan, professor of Neuroscience and an expert in thebiology of sex differences.

While high perinatal androgen levels are specific to males, the researchers found that while in utero, females exposed to male levels of perinatal androgens develop mast cells that behave more like those of males.

For these females, exposure to the perinatal androgens reduced their histamine levels and they also exhibited less-severe anaphylactic responses as adults, says Mackey, who is currently a veterinary medical student at North Carolina State University.

In addition to paving the way for improved and potentially novel therapies for sex-biased immunological and other diseases, future research based will help researchers understand how physiological and environmental factors that occur early in life can shape lifetime disease risk, particularly mast cell-mediated disease patterns.

While biological sex and adult sex hormones are known to have a major influence on immunological diseases between the sexes, were learning that the hormones that we are exposed to in utero may play a larger role in determining sex differences in mast cell-associated disease risk, both as adults and as children, Moeser said.

Reference: Mackey E, Thelen KM, Bali V, et al. Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood. Proc Natl Acad Sci USA. Published online September 11, 2020:201915075. doi:10.1073/pnas.1915075117.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:
How the Hormones You're Born With Influence Disease Risk - Technology Networks

Posted in Stem Cells | Comments Off on How the Hormones You’re Born With Influence Disease Risk – Technology Networks

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) – BioSpace

Posted: September 16, 2020 at 1:55 pm

NEW YORK, Sept. 16, 2020 /PRNewswire/ --The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with Multisystem Inflammatory Syndrome in Children (MIS-C). The trial is being led by Dr. Joanne Kurtzberg at Duke University to determine if infusions of hCT-MSCs are safe and can suppress the hyper-inflammatory response and positively impact the symptom course and duration, as well as the long-term effects of this life-threatening syndrome. The hCT-MSCs are manufactured in the Robertson GMP Cell Manufacturing Laboratory at Duke. The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application, and Dr. Kurtzberg will proceed with a multi-site pilot study later this month.

As the school year is underway more children are being diagnosed with the SARS-CoV-2 virus. According to the American Academy of Pediatrics (AAP), the cumulative number of coronavirus cases diagnosed in children has more than tripled between July 2 and September 3 from 165,845 to 513,415. As of September 3rd, children represent at least 9.8% of diagnosed cases in the U.S. and in states such as Alaska, Minnesota, Tennessee, South Carolina, New Mexico and Wyoming, children account for more than 15 percent of total cases. Some of these children have developed very serious disease. The Centers for Disease Control and Prevention reported that as of September 3rd at least 792 children in 42 states have been diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C) and 16 have died.

The Principal Investigator of the study, Joanne Kurtzberg, MD, is the Jerome Harris Distinguished Professor of Pediatrics; Professor of Pathology; Director, Marcus Center for Cellular Cures; Director, Pediatric Blood and Marrow Transplant Program; Director, Carolinas Cord Blood Bank; Co-Director, Stem Cell Transplant Laboratory at Duke University School of Medicine/Duke Health and a leader in transplantation, cell therapy, and regenerative medicine in children. Clinical sites include Duke University (Durham, NC), Children's Healthcare of Atlanta (Atlanta, GA), New York Medical College (Valhalla, NY), and others as cases occur.

"We hope this is just the beginning of our ability to support the development of cell therapies to treat COVID-19 Related Multisystem Inflammatory Syndrome in Children," said Dr. Robin Smith,president of the Cura Foundation. "As students across the country return to in-class instruction, it is more important now than ever to ensure we are equipped with potential treatment options to care for children who develop this serious disease."

About the Sponsors

The Cura Foundationleads a global health movement with the goal to improve human health. Cura unites public and private sectors, partnering with doctors, patients, business leaders, philanthropists and thought leaders to create a collaborative network that tackles major health issues and accelerates funding to advance innovations in medicine. Cura believes that by encouraging interdisciplinary approaches to medicine, promoting preventative measures and advancing the development of breakthrough medical technologies you can improve access to care, streamline health care delivery and eliminate social disparities in health care. The Cura Foundation is a nonsectarian, nonpartisan, public and tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code. For more information, please visit: https://thecurafoundation.org/

The Marcus Foundationwas founded in 1989 by Bernie Marcus, co-founder and former CEO of The Home Depot, to support programs in Children and Youth Development, Community, Free Enterprise, National Security, Veterans, Jewish Causes, Healthcare and Medical Research.

Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 46 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and 10 countries. Learn more about Sanford Health's transformative work to improve the human condition at sanfordhealth.orgor Sanford Health News.

Duke Healthconceptually integrates the Duke University School of Medicine, Duke-NUS Medical School, Duke University School of Nursing, Duke University Health System, Private Diagnostic Clinic (Duke physicians practice), and incorporates the health and health research programs within the Duke Global Health Institute as well as those in schools and centers across Duke University, including the Duke-Robert J. Margolis Center for Health Policy.

Duke Health is committed to conducting innovative basic and clinical research, rapidly translating breakthrough discoveries to patient care and population health, providing a unique educational experience to future clinical and scientific leaders, improving the health of populations, and actively seeking policy and intervention-based solutions to complex global health challenges. Underlying these ambitions is a belief that Duke Health is a destination for outstanding people and a dedication to continually explore new ways to help our people grow, collaborate and succeed.

Alliance for Cell Therapy Now(ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. Seehttp://allianceforcelltherapynow.org/

Contact

The Cura FoundationRobin Smith, MD, +1-212-584-4176rsmith@thecurafoundation.com

View original content:http://www.prnewswire.com/news-releases/fda-approves-study-to-investigate-the-use-of-cell-therapy-to-treat-covid-19-related-multisystem-inflammatory-syndrome-in-children-mis-c-301131904.html

SOURCE Alliance for Cell Therapy Now

Read more from the original source:
FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) - BioSpace

Posted in New Mexico Stem Cells | Comments Off on FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) – BioSpace

Research interns get creative around science and social change in the summer of COVID-19 – Princeton University

Posted: September 16, 2020 at 1:55 pm

When the pandemic shut down almost all on-campus research,students who had arranged in-person summer research internships needed to pivot quickly.

In a typical year, the Office of the Dean of the College (ODOC) sponsors summer research opportunities for undergraduate students both on- and off-campus, complete with weekly workshops, lectures and community-building activities. But this year, as the students and mentors re-imagined their research plans to become projects that could be accomplished from home, two ODOC programs the Office of Undergraduate Research (OUR) and the Program in Community-Engaged Scholarship (ProCES) also re-invented their support structures, creating online check-ins and workshops to replace group lunches, digital bonding activities in place of in-person game nights, and stress management workshops for students juggling an unprecedented combination of challenges.

Many students found that their planned internships couldnt make the pivot to remote work, so Trisha Thorme, the ProCES director, created a new pathway where students who had lost their summer opportunities could propose new research-based nonprofit internships. Prior to that, Thorme had planned to oversee six local Derian ProCES interns. (In past years, shes had as many as 12.) So many students took advantage of the new pathway that Thorme had an unprecedented 25 remote Derian interns this summer.

In past years, the students wrapped up their summers by preparing and presenting research talks and posters. In 2020, OUR students created intern profiles and research videos to be shared with incoming Princeton students in the Freshman Scholars Institute and other members of the Princeton community, while the ProCES interns prepared reports and presentations for their host organizations and developed 90-second pitches that describe their summer work and its impact.

Overall, what Im most impressed by is just the level of creativity and resilience that student researchers have shown, to adapt to the situation, said Pascale Poussart, the OUR director, who oversees ReMatch+, OURSIP and the Summer Research Colloquium (SRC), a weekly community-building program for OUR research interns and mentors.

Allison Yang 23 studied how brains sync up during communication as part of her research internship, funded by the Office of Undergraduate Researchs Student Initiated Internships (OURSIP).

ReMatch, part of a collaboration between ODOC and the Graduate School, is a year-long program that builds mentoring relationships between undergraduates and graduate students or postdoctoral researchers three groups that didnt often interact, historically. In the fall, ReMatch first-years and sophomores meet with ReMatch graduate mentors to find their match, and in the spring, the mentor-mentee pairs can apply for ReMatch+, a paid summer research internship. Of the 10 ReMatch+ projects funded this year, one focused on closing the sex gap in neuroscience research, while others investigated genes associated with breast cancer and breastfeeding and studied how rats make decisions.

"While this year looked very different from past summers, it was great to see how the ReMatch+ graduate and undergraduate participants built strong research relationships, despite having shifted to a virtual environment," said Christine Fecenko Murphy, the assistant dean for academic affairs in the Graduate School, whoco-directsthe ReMatch Program.

Jessica Brice of the Class of 2022 was matched with Lauren Feldman, a fifth-year graduate student who works in the lab of Joel Cooper, a professor of psychology. Brices original research went in a new direction after the death of George Floyd on May 25. She ran a linguistic analysis of the statements provided by 179 university leaders presidents, provosts and chancellors of 112 predominantly white institutions and 67 historically Black colleges and universities looking for hundreds of phrases about indirect biasand structural inequality.

Her preliminary results suggest that this summer, colleges and universities were more willing to publicly recognize and explicitly describe racist behavior than they had been in the past. She also identified some trends in language use. For example, she found that statements from predominantly white institutions were somewhat more likely to use more social unity words like solidarity, community and together than HBCUs, while HBCU statements were many times more likely to use words like defund, restructure and abolish.

This experience has not only given me some exciting ideas for my junior paper but strengthened my interest in pursuing a career in research psychology, Brice said.

Jessica Brice 22 ran a sophisticated analysis of statements made by 179 university leaders after the death of George Floyd, quantifying their use of words and phrases like solidarity and structural inequality, during her OUR-sponsored ReMatch+ internship.

Video by Jessica Brice 22

Every year, OURSIP provides grants to Princeton first-years and sophomores (and occasionally juniors) who have independently created or secured an unpaid faculty-mentored research internship over the summer.

This summer, OURSIP supported 30 projects, which ranged from a study of cholesterol at the molecular level to designing a cheating-proof sports tournament, studying little-known proteins that are key to photosynthesis, and investigating magic-angle graphene.

Allison Yang of the Class of 2023 was both an OURSIP intern and the SRC program assistant, with responsibility for organizing and running weekly social events online to build community between the geographically scattered interns. She developed a truly fun and creative line-up of events so students could connect with each other informally, said Poussart.

Yangs OURSIP project used fMRI brain scans to look for neural synchrony brains syncing up together during communication. She tracked brain activity simultaneously in pairs of volunteers, as one student gave another instructions on simple tasks, like how to find Waldo in a picture or how to design an avatar. Her goal was to better understand how neural activity corresponds to effective communication.

Id definitely recommend participating in OURSIP, even if you dont plan on a research-related career, Yang said. The experience of research truly benefits your problem-solving and analytical skills, and the process of discovery is so exciting!

Avery Goldinger '21 created a 17-week STEM curriculum as part of her Derian ProCES Internship. She wrote 70 lesson plans, teacher training materials and more, in partnership with the Boys and Girls Club of Western Pennsylvania.

Video by Avery Goldinger, Pace Center

In these internships, rising sophomores, juniors and seniors apply academic skills in service of a local nonprofit or governmental organization. Each student tackles specific projects and research under the direction of the organization theyre partnering with at least one project that can be completed during the internship and another, larger project that both addresses the nonprofits needs and launches junior paper or senior thesis work.

This results in extraordinarily varied final products: Avery Goldinger, Class of 2021, created a 17-week STEM curriculum, including 70 lesson plans and teacher training materials, in partnership with the Boys and Girls Club of Western Pennsylvania an organization whose robotics club had played a key role in helping her be the first member of her family to attend college.

When all is said and done, the best thing about STEM education is that its not just about STEM, she said. Speaking from personal experience, these students think theyre just learning about robots or clouds or blood cells when theyre also learning about communication, confidence and what it means to be a good teammate. This project gave me the chance to give back to my community, and I am so grateful for it. Hopefully, it will inspire upcoming generations of Pittsburgh students to pursue higher education.

Jonathan Wang of the Class of 2021 worked with Prevention Point Philadelphia, a harm reduction center serving people affected by opioid addiction. Afterworking with their program treating opioid use disorder with behavioral therapy and medications, he spent this summer reviewing anonymized patient charts to document how housing insecurity affects treatment outcomes. He found that patients experiencing housing insecurity, particularly street homelessness, were less likely to stay in treatment, take their medications regularly or attend their appointments, compared to their stably housed counterparts. Housing is health care, Wang said. Health care is so much messier than simply fighting diseases; its fighting the structures that give rise to them. I hope that I can enter a career as a health care provider to fight for the social changes I want to see.

Jonathan Wang 21 spent his summer working with Prevention Point Philadelphia to track how housing insecurity affects treatment outcomes for people affected by opioid addiction, as part of his Derian ProCES internship.

Another ProCES Derian intern, Fernanda Romo Herrera Ibarrola of the Class of 2022, helped the families of disappeared people in Mexico with the organization FUNDAR. Ive gotten to work alongside some really amazing coworkers, who come from all kinds of different academic backgrounds from law, social sciences like sociology, politics, history, even psychology, she said. Its really given me a much closer and deeper look at the kind of work that civil society organizations can do: the ways they can pressure governments, push for certain policies and accomplish things by advocating for a more just society.

Ashley Morales, now a junior in the Princeton School of Public and International Affairs, spent the summer working for Cristosal, a human rights nonprofit working in El Salvador, Guatemala and Honduras. Her research project examined transitional justice the public reckoning and public reconciliation after genocide or state-sanctioned violence in an attempt to regain trust in government and transform institutions.

She had originally planned to focus solely on Central America, but she pivoted after the protests in the United States suggested that the U.S. was beginning its own public reconciliation with years of systemic racism. She compared police brutality and extrajudicial executions, historical erasure and memory, and impunity. This project has shown me the power of academic research in framing social justice topics and convincing others to advocate for a cause, she said. "I have been so grateful for this opportunity, especially as someone who intends to pursue international law in the future. We must advocate for human rights issues across multiple regions, including the United States, in order to achieve universal peace, accountability and justice.

These projects give students extraordinary opportunities to make tangible contributions to real-world problems and see the links between their academic work and serving the public good, said Thorme. We really want the students to see how important knowledge, research and information are in the process of creating social change.

Fernanda Romo Herrera Ibarrola 22 spent her Derian ProCES internship worked with thefamilies of disappeared people in Mexicowith the organizationFUNDAR.

Video by Fernanda Romo Herrera Ibarrola

See the rest here:
Research interns get creative around science and social change in the summer of COVID-19 - Princeton University

Posted in New Mexico Stem Cells | Comments Off on Research interns get creative around science and social change in the summer of COVID-19 – Princeton University

20 Coronavirus symptoms | What is smell training and why it generates so much interest during the pandemic – Explica

Posted: September 16, 2020 at 1:55 pm

We collected testimonies from people who lost their sense of smell, some due to covid-19. But an increasingly popular therapy offers a light at the end of the tunnel

It is as if an invisible barrier separates me from reality, said Saulo. Its as if my memories have been erased, Ana said.

Everything smells the same to me, Virginia said.

Saulo and Ana live in Brazil, Virginia is Mexican but resides in the United States. All three lost their sense of smell, and in some cases taste, due to the new coronavirus.

BBC Mundo contacted them through AbScent.org, a website that offers help to those who are left, totally or partially, without the ability to perceive odors.

On March 13, I had about 1,500 people in the Facebook group, Chrissi Kelly, founder of AbScent, told BBC Mundo.

Now I have three Facebook groups with about 11,000 members in total. Suddenly they started contacting me from Iran, Italy, Spain and then many people from Latin America .

The site became a barometer of the impact of the coronavirus.

Science Photo Library It is essential to perform the smell rehabilitation exercises while maintaining concentration instead of thinking about what you will do the rest of the day.

In AbScent, users find information about a therapy that, although it was already offered before covid-19, is gaining popularity due to the pandemic.

Therapy is the olfactory training, A series of exercises to recover the perception of smells, and in the case of many people, a sense of normality in their lives.

What is the loss of smell and what is its emotional cost?

How effective is olfactory rehabilitation and what is its scientific basis?

Numerous investigations established a connection between smell problems and the new coronavirus.

In our study, which was carried out including 15 hospitals throughout Spain, of 989 patients with covid-19 a 53% had altered smellAdriana Izquierdo Domnguez, allergology specialist at the Teknn Medical Center in Barcelona and member of the Spanish Society of Otorhinolaryngology (SEORL), told BBC Mundo.

But the new coronavirus is only the latest in a long list of possible causes.

Courtesy Saulo SegretoSaulo Segreto has been training for more than four months. After losing my sense of smell, I feel as if an invisible barrier separated me from reality.

Patricia Portillo Mazal, otolaryngologist and smell and taste specialist at the Italian Hospital in Buenos Aires, explained that one of the most frequent causes of loss of smell are viral infectionslike colds and flu .

Another common origin are blows to the head or face that damage some part of the olfactory system, added the expert.

Sometimes the reason for the loss of smell is not identified, which can also have different degrees.

There is talk of anosmia when there is no smell and hyposmia when perception is partial, explained Portillo Mazal.

But sometimes the most limiting thing is still the call parosmia, the distorted smells, when a coffee smells different to you from what you remembered, many times as something unpleasant .

And within the parosmia there is even the phantosmia, which is to smell a smell that is not there but that you perceive .

Loss of smell can profoundly affect well-being, as the story of Chrissi Kelly, the creator of AbScent, illustrates.

Kelly, who was born in the United States and resides in England, lost her sense of smell from a viral infection in 2012.

Between about six and nine months later I fell into a deep depression, he told BBC Mundo.

There is something fundamental that I would like people to understand. Losing your sense of smell is a blow to your well-being, it affects every aspect of your life. Steeth as if you lose the sense of whoandyou wereHe added.

Courtesy Chrissi KellyChrissi Kelly is the founder of AbScent. There is something fundamental that I would like people to understand. Losing your sense of smell is a blow to your well-being, it affects every aspect of your life .

After consulting doctors who looked into your nose without giving you solutions, Kelly began looking for information and attending specialist conferences.

In one of them he found Thomas Hummel, an expert at the Center for Smell and Taste at the University of Dresden in Germany.

Hummel was the first scientist to publish, in 2009, a study evaluating the effectiveness of olfactory training.

When I told my story to Hummel, he listened compassionately for half an hour. It was the first time that I spoke with someone who understood me .

Kelly began attending courses that the German expert gave to specialists and in 2015 ended up founding AbScent.

The site has a YouTube channel with explanatory videos and now has guides in Spanish and Portuguese for users in Latin America.

Many of AbScents readers, such as Saulo, Ana and Virginia, claim to have found on the site that feeling of support that Kelly experienced when she was heard by Hummel.

I went to three ENT specialists, a neurologist and a pneumologist. They even gave me an antiepileptic drug that left me sick. And through tireless searches on the internet I came to AbScent, which it was essential to keep calmSaulo Segreto recounted from Rio de Janeiro.

Courtesy Ana CarboneAna Carbone: I feel despondent when I do not perceive smells like that of my daughter, a perfume, or not knowing if there may be a gas leak.

Saul suffers from parosmia. For me all things fried smell like burning, he said.

Lately I have a horrible smell in a lot of things. Leaves me nauseousSaid Ana Carbone, from Sao Paulo, who suffers from the same.

And I feel upset by not perceiving smells like that of my daughter, a perfume, or not knowing if there may be a gas leak.

In the case of Virginia Mata, some experiences are even difficult to describe.

I went on August 23 from not smelling anything to perceiving a strange smell. Mmy brain doesnt know how to process it to name itIts just kind of weird.

It is not known since when the technique of training the smell has existed, but clinically it has been used for about a decade.

Rehabilitation basically consists of inhale smells, concentrating the mind, at least twice a day.

It has to be every day, and they are short inhalations, more or less than 20 seconds, explained Portillo Mazal.

Courtesy P. Portillo Mazal Patricia Portillo Mazal, a doctor at Hospital Italiano in Buenos Aires, has patients prepare their own kits.

In each exercise they are generally used four jars with different smells.

The four scents used by Hummel in his early studies were rose, lemon, clove and eucalyptus, but other substances can be used.

Portillo Mazal makes his patients prepare your own kits.

I have two variants. ORna is with oilsThey can be made from fruits, flowers, peppermint, or things like lavender, thyme, or cloves. (The patients) put cotton or paper in a bottle and put about 40 drops, renewing every so often.

The other option is a kit with things from the house: I tell my patients to prepare jars with machine coffee, powdered soap, oregano, or chopped chocolate, for example .

AbScentKelly recommends using dark jars so light does not affect scented oils. And he advises not to smell directly from dropper bottles because they limit the dispersion of odorants.

One of the centers that offers this type of rehabilitation in Spain is the Olfactory Training Unit of the Quirnsalud Sagrado Corazn Hospital in Seville.

For two or three weeks, we subject the patients to different smells and different concentrations for 15 to 20 minutes, Dr. Juan Manuel Maza, director of the Unit and a rhinologist and skull base surgeon at the Virgen Macarena University Hospital in Seville.

Gentileza Quiron SaludOne of the centers in Spain that offers rehabilitation is the Olfactory Training Unit of the Quirnsalud Sagrado Corazn Hospital in Seville.

We can train discrimination. With repeated stimulation we get the patient to begin to identify and discriminate that smell .

And after three weeks, patients can access odorants or formulations that they collect in different pharmacies and spend approximately three minutes a day.

A fundamental aspect of training is doing the exercises with great concentration.

You have to be there for that minute and a half of the exercises, not thinking about what you have to do that day, said Portillo Mazal.

Chrissi Kelly also recommends to evoke memories.

Courtesy Virginia MataVirginia Mata: There are things you just take for granted until you no longer have them, like the scent of your favorite perfume or a pizza just delivered by a delivery man.

When you open your bottle with lemon oil, even if you dont smell anything, close your eyes and remember all the details of when you smelled or ate a lemon.

AND you must be attentive to any olfactory message you perceive, even if it is not expected .

Even when she is not concentrating on her exercises, Virginia Mata often tries to evoke a moment, some feeling.

For example, whenever it is raining I try to remember the smell of wet earth that immediately makes me remember those chaotic days of rain and traffic in Mexico City .

In general, about 60% of people who lose their sense of smell recover to some degree, Thomas Hummel told BBC Mundo.

And what our studies show convincingly is that with olfactory training the recovery rate doubles. That is to say, people recover more quickly and completely.

In some cases recovering does not mean smelling exactly the same as before.

Sometimes its like youre in a strange country, there are smells that are like a new reality, Kelly said.

Zara Patel, a professor of otolaryngology and skull base surgery at Stanford University in the United States, also investigated how effective smell therapy is.

The main conclusion of my studies is that olfactory training has a significant benefit, he told BBC Mundo.

And when combined with irrigation with budesonide, a topical steroid, the training helps up to half of patients with olfactory dysfunction.

50% may not seem like a lot, but think that this is a breakthrough of the situation 10 years ago, when we literally had nothing to offer these patients.

Dr. Maza said for his part that between 45 to 70% of the patients they attend recover.

Regarding the duration of training, Hummel speaks of a minimum period of between six and nine months.

In the case of Portillo Mazal, the Argentine specialist tells her patients: Por at least lets set a goal of six months before saying than this does not work.

I tell them that, hopefully, in two months they will have fleeting insights. Or they will suddenly smell the smell of bread, and they will look and there will be a bakery .

The wonder of the system olfactory

How do you explain that inhaling without smelling anything can help restore smell?

To understand why, the first thing to remember is that the olfactory system encompasses a cascade of events not only in the nose, but at the level of the brain.

BBC

On the roof of the nose are the first cells that capture information, the so-called olfactory receptor neuronsExplained Portillo Mazal.

The journey begins there, and from that cell the information goes to the brain, where the first stop is the olfactory bulb, a small but transmission and command center .

From there the information continues to the rest of the brain. A first stop is the most primitive brain, that of emotions. Another is in the zone that allows to identify or discriminate one odor from another.

And it also goes to an area of long-term emotional memory, which is what makes you smell a chocolate and remember that first time with your grandmother .

One of the keys that explain the effectiveness of rehabilitation is that the olfactory system has an extraordinary capacity for regeneration.

A characteristic of the sense of smell that we do not see in other ways is its plasticity, Dr. Hummel explained to BBC Mundo.

Olfactory receptor neurons constantly regenerate.

Along with these receptor neurons there are also two types of cells.

The support cells they help neurons to function properly, said Dr. Portillo Mazal.

And there are also the calls basal cells, which are totipotent like the famous stem cells, and which can be transformed into either of the other two, the support cell or neurons .

Zara Patel explained that basal cells produce new olfactory receptor neurons throughout our lives. By repeatedly stimulating them with exposure to odorants, we are trying to tell them to wake up.

Courtesy JM Maza Dr. Juan Manuel Maza: Smell is a sense that is also closely linked to taste, and part of the smells can be recognized with some chemoreceptors on the tongue.

Stimulation also produces changes in the brain.

At one time it was believed that regeneration occurred only in neurons at the level of the roof of the nose, said Portillo Mazal.

But thanks to functional resonance it was seen that the brain also becomes more agile, manages to do more with the little information it receives, so the improvement is also due to plasticity at the level of the brain .

Maza reminds that in some cases it is even possible to resort to alternative ways of recovery.

Smell is a sense that is also closely linked to taste, and some odors can be recognized with some chemoreceptors on the tongue that depend on other nerves that do not have to be damaged .

Portillo Mazal pointed out that smell training is to improve taste as well as smell, because taste is largely made up of smell.

I frequently tell my patients that if they are doing the smell coffee exercise, for example, that they do it twice a day, once a day also drink some coffee savoring it.

Read the original here:
20 Coronavirus symptoms | What is smell training and why it generates so much interest during the pandemic - Explica

Posted in New Mexico Stem Cells | Comments Off on 20 Coronavirus symptoms | What is smell training and why it generates so much interest during the pandemic – Explica

Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice – PRNewswire

Posted: September 15, 2020 at 8:59 am

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Locanabio, Inc., a leader in RNA-targeted gene therapy, today announced that results from a preclinical study of the company's therapeutic systems for the potential treatment of myotonic dystrophy type 1 (DM1) were published in Nature Biomedical Engineering. For the full article, titled "The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy," please visit: https://www.nature.com/articles/s41551-020-00607-7

Scientists at Locanabio, working with academic collaborators at UC San Diego School of Medicine and the University of Florida, assessed whether an RNA-targeting CRISPR Cas9 system (RCas9) could provide molecular and functional rescue of dysfunctional RNA processing in a DM1 mouse model. The RCas9 system was administered with one dose of an AAV gene therapy vector. Results in both adult and neonatal mice and using both intramuscular and systemic delivery showed prolonged RCas9 expression even at three months post-injection with efficient reversal of molecular (elimination of toxic RNA foci, MBNL1 redistribution, reversal of splicing biomarkers) and physiological (myotonia) features of DM1.Importantly, there were no significant adverse responses to the treatment.

"These results are consistent with earlier findings from several in vitro studies in muscle cells derived from DM1 patients published by Locanabio's scientific co-founder Dr. Gene Yeo of UC San Diego and further indicate the significant potential of our RNA-targeting gene therapy as a DM1 treatment," said Jim Burns, Ph.D., Chief Executive Officer at Locanabio. "Data show that our RNA-targeting system is able to destroy the toxic RNA at the core of this devastating genetic disease and thereby correct the downstream molecular and biochemical changes that result in myotonia, which is a hallmark symptom of DM1. We are pleased that Nature Biomedical Engineering recognizes the value of these preclinical data and we look forward to further advancing this developmental program to the benefit of DM1 patients."

"Currently available treatments for DM1 can improve specific symptoms but do not target the underlying biology and cause of the disease. These data demonstrate that RNA-targeting systems may efficiently and specifically eliminate toxic RNA repeats that cause DM1 and potentially lead to a more effective treatment option for patients," said Dr. Yeo. "The results also indicate that RNA-targeting gene therapy has potential applications in the treatment of other diseases, such as Huntington's disease and certain genetic forms of ALS, which are also caused by a buildup of toxic RNA repeats."

These studies were funded in part by the Muscular Dystrophy Association (MDA). "We are delighted to support Locanabio's recent work in myotonic dystrophy. These preclinical results represent a promising advance and a novel scientific approach for a group of patients who represent a major unmet medical need," said Sharon Hesterlee, Ph.D., Chief Research Officer, MDA.

About Locanabio, Inc.

Locanabio is the global leader in developing a new class of genetic medicines. Our unique and multi-dimensional approach uses gene therapy to deliver RNA binding protein-based systems to correct the message of disease-causing RNA and thereby change the lives of patients with devastating genetic diseases. These broad capabilities delivered via gene therapy enable Locanabio to potentially address a wide range of severe diseases with a single administration. The company is currently advancing programs in neuromuscular, neurodegenerative and retinal diseases. For more information, visit http://www.locanabio.com.

About Myotonic Dystrophy

Myotonic dystrophy type 1 (DM1) is an autosomal dominant genetic disorder affecting skeletal muscle, cardiac muscle, the gastrointestinal tract, and the central nervous system. DM1 is caused by a mutation in the myotonic dystrophy protein kinase (DMPK) gene. This mutation leads to a repeat expansion of the CTG (cytosine-thymine-guanine) trinucleotide. The expanded CTG is transcribed into toxic CUG (cytosine-uracil-guanine) repeats in the DMPK messenger RNA (mRNA). These toxic mRNA repeats lead to disease symptoms including progressive muscle wasting, weakness and myotonia (delayed relaxation of skeletal muscle), a hallmark of DM1. The incidence of myotonic dystrophy has historically been estimated at one in 8,000 individuals worldwide or approximately 40,000 people in the United States.

Media Contact

Brian ConnorBerry & Company[emailprotected]+1-845-702-2620

SOURCE Locanabio, Inc.

http://www.locanabio.com

More:
Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice - PRNewswire

Posted in Gene therapy | Comments Off on Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Mice – PRNewswire

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic…

Posted: September 15, 2020 at 8:59 am

PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.

This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible, said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.

LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.

Lenadogene nolparvovec (tradename: LUMEVOQ) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.

GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ-treated patients (from LUMEVOQ efficacy studies) against those in untreated patients from Natural History studies and GenSights REALITY Natural History Registry.

GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ to the FDA in H2 2021. First-in-human data from GenSights second clinical stage program, GS030, are expected to be available in H2 2021.

About GenSight BiologicsGenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Read the original post:
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic...

Posted in Gene therapy | Comments Off on GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic…

How CRISPR is tackling the troubling immune response thats plagued gene therapy until now – TNW

Posted: September 15, 2020 at 8:59 am

One of the major challenges facing gene therapy a way to treat disease by replacing a patients defective genes with healthy ones is that it is difficult to safely deliver therapeutic genes to patients without the immune system destroying the gene, and the vehicle carrying it, which can trigger life-threatening widespread inflammation.

Three decades ago researchers thought that gene therapy would be the ultimate treatment for genetically inherited diseases like hemophilia, sickle cell anemia, and genetic diseases of metabolism. But the technology couldnt dodge the immune response.

Since then, researchers have been looking for ways to perfect the technology and control immune responses to the gene or the vehicle. However, many of the strategies tested so far have not been completely successful in overcoming this hurdle.

Drugs that suppress the whole immune system, such as steroids, have been used to dampen the immune response when administering gene therapy. But its difficult to control when and where steroids work in the body, and they create unwanted side effects. My colleague Mo Ebrahimkhani and I wanted to tackle gene therapy with immune-suppressing tools that were easier to control.

I am a medical doctor and synthetic biologist interested in gene therapy because six years ago my father was diagnosed with pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer, and the currently available therapeutics usually fail to save patients. As a result, novel treatments such as gene therapy might be the only hope.

[Read: These tech trends defined 2020 so far, according to 5 founders]

Yet, many gene therapies fail because patients either already have pre-existing immunity to the vehicle used to introduce the gene or develop one in the course of therapy. This problem has plagued the field for decades, preventing the widespread application of the technology.

Traditionally scientists use viruses from which dangerous disease-causing genes have been removed as vehicles to transport new genes to specific organs. These genes then produce a product that can compensate for the faulty genes that are inherited genetically. This is how gene therapy works.

Though there have been examples showing that gene therapy was helpful in some genetic diseases, they are still not perfect. Sometimes, a faulty gene is so big that you cant simply fit the healthy replacement in the viruses commonly used in gene therapy.

Another problem is that when the immune system sees a virus, it assumes that it is a disease-causing pathogen and launches an attack to fight it off by producing antibodies and immune response just as happens when people catch any other infectious viruses, like SARS-CoV-2 or the common cold.

Recently, though, with the rise of a gene-editing technology called CRISPR, scientists can do gene therapy differently.

CRISPR can be used in many ways. In its primary role, it acts as a genetic surgeon with a sharp scalpel, enabling scientists to find a genetic defect and correct it within the native genome in desired cells of the organism. It can also repair more than one gene at a time.

Scientists can also use CRISPR to turn off a gene for a short period of time and then turn it back on, or vice versa, without permanently changing the letters of DNA that makes up our genome. This means that researchers like me can leverage CRISPR technology to revolutionize gene therapies in the coming decades.

But to use CRISPR for either of these functions, it still needs to be packaged into a virus to get it into the body. So some challenges, such as preventing the immune response to the gene therapy viruses, still need to be solved for CRISPR-based gene therapies.

Being trained as a synthetic biologist, I teamed up with Ebrahimkhani to use CRISPR to test whether we could shut down a gene that is responsible for the immune response that destroys the gene therapy viruses. Then we investigated whether lowering the activity of the gene, and dulling the immune response, would allow the gene therapy viruses to be more effective.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

CRISPR can precisely remove even single units of DNA. KEITH CHAMBERS/SCIENCE PHOTO LIBRARY/Getty Images

A gene called Myd88 is a key gene in the immune system and controls the response to bacteria and viruses, including the common gene therapy viruses. We decided to temporarily turn off this gene in the whole body of lab animals.

We injected animals with a collection of the CRISPR molecules that targeted the Myd88 gene and looked to see whether this reduced the number of antibodies that were produced to specifically fight our gene therapy viruses. We were excited to see that the animals that received our treatment using CRISPR produced less antibodies against the virus.

This prompted us to ask what happens if we give the animal a second dose of the gene therapy virus. Usually, the immune response against a gene therapy virus prevents the therapy from being administered multiple times. Thats because after the first dose, the immune system has seen the virus, and on the second dose, antibodies swiftly attack and destroy the virus before it can deliver its cargo.

We saw that animals receiving more than one dose did not show an increase in antibodies against the virus. And, in some cases, the effect of gene therapy improved compared with the animals in which we had not paused the Myd88 gene.

We also did a number of other experiments that proved that tweaking the Myd88 gene can be useful in fighting off other sources of inflammation. That could be useful in diseases like sepsis and even COVID-19.

While we are now beginning to improve this strategy in terms of controlling the activity of the Myd88 gene. Our results, now published in Nature Cell Biology, provide a path forward to program our immune system during gene therapies and other inflammatory responses using the CRISPR technology.

This article is republished from The Conversation by Samira Kiani, Associate Professor of Pathology, University of Pittsburghunder a Creative Commons license. Read the original article.

Read next: Your online branding is key to your business success. Heres your roadmap

See original here:
How CRISPR is tackling the troubling immune response thats plagued gene therapy until now - TNW

Posted in Gene therapy | Comments Off on How CRISPR is tackling the troubling immune response thats plagued gene therapy until now – TNW

Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World…

Posted: September 15, 2020 at 8:59 am

-- Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time --

-- Additional poster presentations at WMS will highlight data from Sareptas RNA and gene therapy programs --

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that new data from its most advanced gene therapy programs will be presented at the WMS25 Virtual Congress, the 25th International Annual Congress of the World Muscle Society, being held Sept. 28 Oct. 2.

Sarepta will host a webcast and conference call on Monday, Sept. 28, 2020 at 8:30 a.m. ET, to discuss the results, which include two-year functional data from Study 101 of SRP-9001 for Duchenne muscular dystrophy and 18-month functional results from Cohort 1 in the study of SRP-9003 for Limb-girdle muscular dystrophy Type 2E.

This will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentationsand will be archived there following the call for one year. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 6793650. Please specify to the operator that you would like to join the "Long-term Functional Data from Sareptas Gene Therapy Programs call.

In total, Sarepta will present 16 abstracts at this years meeting. All posters will be available on-demand throughout the Congress beginning on Monday, Sept. 28 at 7:00 a.m. EST. The full WMS25 Virtual Congress program is available here: https://www.wms2020.com/programme/.

Gene Therapy:

RNA Platform:

Natural history and other presentations:

Presentations will be archived under the events and presentations section of the Sarepta Therapeutics website at http://www.sarepta.comforone year following their presentation at WMS25.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com

Media: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

View post:
Long-term functional data from Sarepta Therapeutics' Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World...

Posted in Gene therapy | Comments Off on Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World…

Page 898«..1020..897898899900..910920..»